Isometric Exercise in NTG

NCT ID: NCT03921372

Last Updated: 2019-04-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-26

Study Completion Date

2019-02-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing evidence that dysfunction of ocular microcirculation in the optic nerve influences the progression of glaucoma. It has been shown that flicker light-induced vasodilatation of retinal veins is diminished in patients with glaucoma. Also previous studies indicate that the blood flow autoregulation is impaired in patients with glaucoma. Therefor the ocular perfusion pressure can not be maintained stable during changes of the systemic arterial blood pressure. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the optic disc in Japanese glaucoma patients.

Study Objectives:

To assess the changes in LSFG parameters in patients with normal tension glaucoma, compared to healthy subjects during flicker light stimulation and isometric exercises.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mean Blur Ratio

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Tension Glaucoma (NTG)

Patients with diagnosed NTG

Group Type EXPERIMENTAL

Isometric exercise

Intervention Type DIAGNOSTIC_TEST

Squatting for 5 minutes

Healthy Control Subjects

Subjects with no sign of glaucoma, Age and sex matched

Group Type EXPERIMENTAL

Isometric exercise

Intervention Type DIAGNOSTIC_TEST

Squatting for 5 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Isometric exercise

Squatting for 5 minutes

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal open angle in a gonioscopic examination
* Presence of glaucomatous optic disc changes in biomicroscopy and
* Visual field defects in at least two visual field examinations (Reliability criteria: fixation errors \< 20%, false positives \< 15%, and false negatives \< 33%) Or
* Abnormal circumpapillary retinal nerve fiber layer thinning (RNFL evaluated by OCT)
2. Control group

* Men and women aged over 18 years
* Subject is generally healthy with no current significant or a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination. A significant disorder is defined as a disease or medical condition associated with impaired health status, requiring regular or current medical treatment and/or follow up. For the purposes of this study, an investigator may classify a medical condition as a nonsignificant disorder despite the fact that the subject receives treatment. Subjects having controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or 90-99 mmHg diastolic) are eligible for participation in this study
* Baseline IOP in both eyes below 21 mm Hg
* Normal findings in slitlamp and funduscopic examination

Exclusion Criteria

* a) Study population: patients with normal tension glaucoma
* History of ocular or systemic disease causing optic nerve damage
* History of IOP greater than 21 mm Hg (corrected by CCT)
* Participation in a clinical trial in the 3 weeks preceding the study
* Ocular surgery (including intravitreal injection) during the 3 months preceding the study
* Ametropia \> 6 Dpt
* Smoking
* pre- or perimenopausal women
* Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
* Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading \> 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
* Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
* Blood donation in the 3 weeks preceding the study
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Ocular infection or clinically significant inflammation
* Pregnancy, planned pregnancy or lactating

b) Control group
* Abnormal RNFL
* Visual field defects
* Participation in a clinical trial in the 3 weeks preceding the study
* Ocular surgery (including intravitreal injection) during the 3 months preceding the study
* Ametropia \> 6 Dpt
* Smoking
* Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
* Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading \> 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
* Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
* Blood donation in the 3 weeks preceding the study
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Ocular infection or clinically significant inflammation
* Pregnancy, planned pregnancy or lactating
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Augenabteilung Allgemeines Krankenhaus Linz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Matthias Bolz

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matthias Bolz, Prof.

Role: PRINCIPAL_INVESTIGATOR

Allgemeines Krankenhaus Linz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AKh Linz

Linz, Upper Austria, Austria

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IsometricProtocol2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optical Angiography in Glaucoma
NCT02548676 COMPLETED